Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union Nitric Oxide (EUNO) trial.

Anne GreenoughFabrice DecobertDavid FieldMikko HallmanHelmut D HummlerBaldvin JonssonManuel Sánchez LunaBart Van OvermeireVirgilio P CarnielliJim L PotenzianoJean-Christophe Mercier

Published in: Journal of perinatal medicine (2020)

iNO for prevention of BPD in very premature infants with respiratory distress did not result in long-term benefits or adverse long-term sequelae. In the light of current evidence, routine use of iNO cannot be recommended for prevention of BPD in preterm infants.

Keyphrases

nitric oxide
preterm infants
low birth weight
nitric oxide synthase
hydrogen peroxide
clinical trial
cystic fibrosis
clinical practice
emergency department
phase iii
phase ii
randomized controlled trial
adverse drug